Microbot Medical Showcases LIBERTY Robotic System at Oncology Conference to Drive Commercial Adoption

summarizeSummary

Microbot Medical is attending the Society of Interventional Oncology annual meeting to showcase its LIBERTY Endovascular Robotic System, aiming to accelerate commercial awareness and adoption during its limited market release.

check_boxKey Events

• Showcasing LIBERTY System at SIO Conference

  Microbot Medical is attending the Society of Interventional Oncology (SIO) annual meeting from February 4-8, 2026, to showcase its LIBERTY Endovascular Robotic System.

• First Commercial Exhibition During Limited Release

  This conference marks the first commercial exhibition of the LIBERTY System since its limited market release commenced in late 2025, allowing the company to engage directly with interventional oncologists.

• Strategy to Accelerate Commercial Adoption

  The company aims to share practical insights from current users and offer hands-on demonstrations to accelerate commercial awareness and adoption of the FDA-cleared robotic system, ahead of a full market release planned for April 2026.

auto_awesomeAnalysis

Microbot Medical's participation in the Society of Interventional Oncology annual meeting marks a significant step in the commercialization of its LIBERTY Endovascular Robotic System. This event, serving as the first commercial exhibition during the limited market release, is crucial for gathering physician insights and accelerating market awareness and adoption. The company's strategy to engage directly with interventional oncologists and offer hands-on demonstrations is designed to build commercial traction ahead of the planned full market release in April, which is vital for a medical device company with an FDA-cleared product targeting a multi-billion dollar market.